Chemotherapy-Induced Anemia Global Market Report 2024

The chemotherapy-induced anemia market size has grown strongly in recent years. It will grow from $2.4 billion in 2023 to $2.6 billion in 2024 at a compound annual growth rate (CAGR) of 8.4%. The growth observed in the historical period can be ascribed to the heightened prevalence of cancer and the corresponding increase in chemotherapy treatments. Factors contributing to this trend include an aging population, which leads to a higher incidence of cancer, the expansion of chemotherapy drugs and regimens, improvements in overall cancer survival rates, and increased awareness and diagnosis of anemia as a side effect.

The chemotherapy-induced anemia market size is expected to see strong growth in the next few years. It will grow to $3.46 billion in 2028 at a compound annual growth rate (CAGR) of 7.4%. The anticipated growth in the forecast period can be linked to the development of supportive care in oncology, an increase in healthcare expenditure and infrastructure, the advancement of personalized medicine and targeted cancer therapies, the integration of biomarker-driven treatment approaches, a growing emphasis on early detection and intervention, and the incorporation of digital health technologies in patient management. Noteworthy trends in the forecast period encompass the innovation of novel chemotherapy agents, the integration of machine learning, advancements in cancer research and treatment protocols, the inclusion of artificial intelligence, and collaborative efforts between pharmaceutical companies and healthcare providers.

The anticipated growth in the chemotherapy-induced anemia market is expected to be propelled by the high prevalence of cancer and anemia. Cancer, characterized by uncontrolled cell growth and spreading to other parts of the body, often leads to chemotherapy-induced anemia (CIA) in patients undergoing aggressive chemotherapy, with or without radiation therapy. Medications designed to stimulate red blood cell production in the bone marrow are commonly used to address chemotherapy-induced anemia. For instance, Cancer Research UK projects a 3% increase in the incidence of head and neck cancer in the UK from 2023 to 2025, with a corresponding 12% rise in deaths due to head and neck cancers during the same period. Consequently, the elevated prevalence of cancer and anemia contributes to the growth of the chemotherapy-induced anemia market.

The anticipated growth in the chemotherapy-induced anemia market is expected to be boosted by increased research and development expenditure. Research and development expenditure refers to the financial investment made by a company in developing, designing, and enhancing its products. Higher investments in research and development can foster innovation and productivity, leading to the formulation of novel drugs for treating chemotherapy-induced anemia. For instance, the European Federation of Pharmaceutical Industries and Associations reported that in 2021, European health industries invested approximately 41.5 billion euros ($44.47 billion) in research and development, marking an increase from 39.65 billion euros ($42.49 billion) in 2020. Thus, the upsurge in research and development expenditure is a driving force behind the chemotherapy-induced anemia market.

Major players in the chemotherapy-induced anemia market are directing their efforts towards the development of innovative therapies, such as myeloprotection therapy, specifically for extensive-stage small cell lung cancer, in order to establish a competitive advantage. Myeloprotection therapy involves a medical strategy aimed at protecting the bone marrow from the damage caused by chemotherapy, thereby reducing associated complications. For example, in February 2021, G1 Therapeutics Inc., a biopharmaceutical company based in the United States, secured FDA approval for COSELA (trilaciclib). This marked the first myeloprotection therapy designed to mitigate chemotherapy-induced myelosuppression, a condition characterized by reduced blood cell production in the bone marrow, which can lead to complications such as neutropenia, anemia, and thrombocytopenia in patients with extensive-stage small-cell lung cancer. Administered prior to chemotherapy, COSELA serves to safeguard the bone marrow, decreasing the incidence and duration of severe neutropenia. It provides multilineage protection, impacting anemia and reducing the need for rescue interventions.

Key players in the chemotherapy-induced anemia market are actively pursuing the development of oral treatments, such as oral HIF-PHI, to achieve positive outcomes and optimize their market profitability. Oral HIF-PHI, or Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor, is a medication administered orally that stimulates the production of red blood cells by modulating oxygen-sensing pathways. For instance, in August 2021, FibroGen Inc., a U.S.-based biotechnology company, reported positive results from the Phase 2 WHITNEY study of roxadustat for chemotherapy-induced anemia (CIA) in non-myeloid malignancies. The study successfully met its primary efficacy endpoint, showing the maximum change in hemoglobin within 16 weeks without the need for red blood cell transfusion. Roxadustat demonstrated efficacy and was well-tolerated in the study's 92 patients. Chemotherapy-induced anemia, a common chemotherapy side effect, is often inadequately treated, impacting patient outcomes. Roxadustat, as an oral HIF-PHI, supports erythropoiesis and is also under investigation for anemia associated with chronic kidney disease.

In August 2022, CSL Limited, an Australia-based biotechnology company, acquired Vifor Pharma AG for an undisclosed amount. This strategic acquisition aimed to diversify CSL's business by integrating Vifor's franchises, thereby strengthening CSL's position in a high-growth and less competitive sector. Vifor Pharma AG is a Switzerland-based pharmaceutical company with a pipeline of drugs for chemotherapy-induced anemia.


Major companies operating in the chemotherapy-induced anemia market report are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Amgen Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Astellas Pharma Inc., Fresenius Kabi AG, Hospira Inc., Dr. Reddy’s Laboratories Ltd., Biocon Ltd., 3SBio Group, FibroGen Inc., Karger AG, Avesthagen Ltd., Blausen Medical Communications Inc., Aileron Therapeutics Inc.

North America was the largest region in the chemotherapy-induced anemia market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chemotherapy-induced anemia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the chemotherapy-induced anemia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The various categories of chemotherapy-induced anemia include mild, moderate, severe, and life-threatening anemia. Mild anemia denotes a condition where an individual has hemoglobin levels below the standard range. Treatment protocols, including red blood cell (RBC) transfusion, erythropoiesis-stimulating agents (ESAs), and iron supplementation, are applicable in diverse end-user settings such as hospitals, ambulatory surgical centers, multispecialty clinics, cancer research centers, and cancer rehabilitation centers.

The chemotherapy-induced anemia report is one of a series of new reports that provides chemotherapy-induced anemia market statistics, including the chemotherapy-induced anemia industry's global market size, regional shares, competitors with chemotherapy-induced anemia market share, detailed chemotherapy-induced anemia market segments, market trends, and opportunities, and any further data you may need to thrive in the chemotherapy-induced anemia industry. This chemotherapy-induced anemia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The chemotherapy-induced anemia market consists of sales of androxy oral, epoetin alfa injection, epogen injection, procrit injection, and aranesp injection. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.


The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).


The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.